RECORD // Company

MetaVia Inc.

Formerly: NeuroBo Pharmaceuticals, Inc.; Gemphire Therapeutics Inc.

Built 2026-11-21T07:36:32Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (3)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001104659-26-126541

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-4,623,0003 months ended 2026-09-3010-Q2026-11-130001104659-26-1265412026-11-21 07:36 UTCReport an error
Cash and cash equivalents$8,778,000at 2026-09-3010-Q2026-11-130001104659-26-1265412026-11-21 07:36 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001638287
Ticker
MTVA
EIN
472389984
CUSIP
64132R503
Record ID
sx:sec:0001638287

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-18SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-18SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
State of incorporationDE2026-11-18SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
Fiscal year end (MMDD)12312026-11-18SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
Business address545 CONCORD AVENUE, SUITE 210, CAMBRIDGE, MA, 021382026-11-18SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
ExchangesNasdaq2026-11-18SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-12,973,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 07:36 UTCReport an error
Total assets (at 2025-12-31)$11,123,0002025-12-3110-K, XBRL Assets2026-11-21 07:36 UTCReport an error
Stockholders' equity (at 2025-12-31)$5,333,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 07:36 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$10,278,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 07:36 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-15,701,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 07:36 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$2,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 07:36 UTCReport an error
Operating lease liabilities (at 2025-12-31)$210,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 07:36 UTCReport an error
Form D total offering amount (D filed 2025-05-15)$10,000,0002025-05-15D2026-11-21 07:36 UTCReport an error
Form D total amount sold (D filed 2025-05-15)$10,000,0002025-05-15D2026-11-21 07:36 UTCReport an error
Form D industry groupBiotechnology2025-05-15D2026-11-21 07:36 UTCReport an error
Form D revenue rangeDecline to Disclose2025-05-15D2026-11-21 07:36 UTCReport an error
Form D date of first sale2025-05-082025-05-15D2026-11-21 07:36 UTCReport an error
8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (filed 2026-11-18)On November 17, 2026, MetaVia Inc. (the “Company”) received written notice from the Nasdaq Stock Market (“Nasdaq”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders’ equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards. Under applicable Nasdaq rules, the Company has 45 calendar days from the date of the notice, or until January 4, 2027, to…2026-11-18SEC EDGAR 8-K 0001104659-26-129393 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 7.01, Regulation FD Disclosures (filed 2026-11-17)On November 17, 2026, MetaVia Inc. (the “Company”) issued a press release announcing that the last patient has completed the final study visit for its Phase 1 clinical trial evaluating DA-1726, a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references…2026-11-17SEC EDGAR 8-K 0001104659-26-128856 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 7.01, Regulation FD Disclosures (filed 2026-11-16)On November 16, 2026, MetaVia Inc. (the “Company”) issued a press release announcing positive preclinical data from a head-to-head study comparing DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, with retatrutide, a triple GLP1R/GIPR/GCGR agonist. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference. The information in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…2026-11-16SEC EDGAR 8-K 0001104659-26-127718 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-16)On November 14, 2026, the Company presented positive preclinical data from a head-to-head study comparing DA-1726, a novel dual OXM analog targeting both GLP1R and GCGR, with retatrutide, a triple GLP1R/GIPR/GCGR agonist. The study evaluated DA-1726 and retatrutide in diet-induced obese mice, assessing body weight, food intake, body composition, plasma metabolic parameters and thermogenesis-related gene expression. Animals received twice-weekly subcutaneous injections of DA-1726 at 300 or 500 nmol/kg or retatrutide at 100 or 200 nmol/kg for approximately three weeks. The higher doses were selected based on pharmacokinetic exposure estimates intended to approximate clinical exposures at 48…2026-11-16SEC EDGAR 8-K 0001104659-26-127718 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-13)On November 13, 2026, MetaVia Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).2026-11-13SEC EDGAR 8-K 0001104659-26-126540 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-13)On November 13, 2026, the Company posted an updated corporate presentation to its website at https://ir.metaviatx.com/events-presentations/presentations, which the Company may use from time to time in connection with presentations, investor communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.2 to this Report and is incorporated herein by reference. Information contained on or accessible through any website reference in the press release or the corporate presentation is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release and the…2026-11-13SEC EDGAR 8-K 0001104659-26-126540 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
Largest institutional holder #1 (13F as filed): JANE STREET GROUP, LLC$176,7232026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #2 (13F as filed): CITADEL ADVISORS LLC$87,5252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #3 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$30,4782026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #4 (13F as filed): UBS Group AG$18,5152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #5 (13F as filed): Scientech Research LLC$17,1802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #6 (13F as filed): Aries Wealth Management$14,3002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$12,7542026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD FIDUCIARY TRUST CO$9,9242026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #9 (13F as filed): Tower Research Capital LLC (TRC)$3,1792026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #10 (13F as filed): SBI Securities Co., Ltd.$3862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.